EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 915 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... March 31, 2021 Reunión anual de la American Society of Clinical Oncology (ASCO) de... June 3, 2022 Load more HOT NEWS ESMO Calls for the European Commission to Propose an EU Directive... Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with... Study Offers Insights on Health Problems among AYA Cancer Survivors Targeting Inflammation Emerges as a Strategy for Treating Cancer
